AI Medical Imaging Approved by China's NMPA: Cancer Screening Enters the 'Minute-Level' Era
China's NMPA approves the first AI cancer screening system MedSight Pro, covering five high-incidence cancers with a 3-minute scan time and over 97% accuracy.
Approval
China's National Medical Products Administration (NMPA) officially granted Class III medical device registration to the AI cancer screening system MedSight Pro today. This is China's first approved AI screening system covering multiple cancer types.
Developed jointly by BGI Genomics and Tsinghua University, MedSight Pro can perform early screening for five high-incidence cancers: lung, liver, gastric, colorectal, and breast cancer.
Core Capabilities
Screening Process
After a patient completes a CT or MRI scan, MedSight Pro completes full analysis within 3 minutes, outputting:
- Positive/negative judgment
- Suspected lesion location and size annotations
- Malignancy probability score (0-100%)
- Recommended follow-up plan
Accuracy Data
| Cancer Type | Sensitivity | Specificity | Early-Stage Detection Rate (Stage I) |
|---|---|---|---|
| Lung cancer | 97.3% | 94.1% | 91.2% |
| Liver cancer | 96.8% | 95.5% | 88.7% |
| Gastric cancer | 95.2% | 93.8% | 85.3% |
| Colorectal cancer | 97.9% | 94.6% | 90.1% |
| Breast cancer | 98.1% | 95.2% | 92.4% |
vs. Traditional Methods
| Dimension | Traditional Manual Reading | MedSight Pro |
|---|---|---|
| Reading time | 15-30 minutes | 3 minutes |
| Early-stage (Stage I) detection rate | 40-55% | 85-92% |
| Miss rate | 8-15% | <3% |
| Doctor workload | High | Low (only needs to review AI markings) |
Rollout Plan
Trials have been completed at Peking Union Medical College Hospital, Shanghai Ruijin Hospital, and Guangzhou Zhongshan Hospital. Next steps:
- Q3 2027: Expand to 50 top-tier (Class A) hospitals
- Q4 2027: Include in some provincial/municipal medical insurance reimbursement catalogs
- 2028: Cover major city tertiary hospitals nationwide
Cost
A single screening is expected to cost ¥800-1,200; after insurance coverage, patient copay could drop to ¥200-400.
Significance
The Director of the Cancer Hospital, Chinese Academy of Medical Sciences stated:
"The biggest bottleneck in cancer screening isn't technology—it's coverage rate. Our goal is to detect cancer at Stage I, raising the cure rate to over 90%."
This article is fictional and for entertainment purposes only.
Disclaimer
This article is demo content on the site, consistent with the notice at the top: it may be fictional or synthetic. Do not use it as a basis for real decisions. Do not cite it as factual reporting.